New paper (method D for PE 0.90) [Two-Stage / GS Designs]

posted by Helmut Homepage – Vienna, Austria, 2011-04-18 14:58 (5534 d 11:15 ago) – Posting: # 6915
Views: 31,080

Dear all,

the preprint of a new paper is available:

Montague TH, Potvin D, DiLiberti CE, Hauck WW, Parr AF, Schuirmann DJ. Additional results for 'Sequential design approaches for bioequivalence studies with crossover designs' Pharm Stat. 2011. 10.1002/pst.483


Methods B and C (α 0.0294) showed non-negligible inflation of the Type I error rate (i.e., >5.2%) for a PE of 0.90 (instead of 0.95 in the 2008 paper). Method D (α 0.028) preserves the overall α and is therefore recommended. It might be possible to adjust the α level for methods B/C as well, but this has not been evaluated yet. Also:

"[…] we have not considered cases where the desired power used in the method is anything other than 80%. Increasing the power used in the methods from 80 to 90% would be expected to have similar direction of effect as decreasing the GMR used in the methods from 0.95 to 0.90. Ongoing work is seeking to generalize the methods considered in this paper and the earlier paper."


Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,653 posts in 4,991 threads, 1,571 registered users;
133 visitors (0 registered, 133 guests [including 50 identified bots]).
Forum time: 02:14 CEST (Europe/Vienna)

To propose that poor design can be corrected by subtle analysis techniques
is contrary to good scientific thinking.    Stuart J. Pocock

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5